Bradley Wasson, DO
Family Medicine · Arlington, TXNPI 1386604825
Payments from drug & device makers
Across 954 payments — averaging $769.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$634K
- Merck$68K
- Pfizer$19K
- Sanofi Pasteur Inc.$10K
- Biohaven Pharmaceuticals, Inc.$1K
- Novo Nordisk$343
- plus $2K from 27 others
What the payments were for
- Consulting fees$17,9562%
- Speaking & faculty fees$559,05076%
- Travel & lodging$135,43218%
- Food & beverage$21,2583%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 663 | $633,539 |
| Merck | 93 | $67,784 |
| Pfizer | 32 | $19,029 |
| Sanofi Pasteur Inc. | 20 | $9,602 |
| Biohaven Pharmaceuticals, Inc. | 1 | $1,200 |
| Novo Nordisk | 21 | $343 |
| Amgen | 17 | $286 |
| Lilly USA, LLC | 16 | $265 |
| AbbVie(2 entities) | 14 | $257 |
| Abbott | 11 | $249 |
| Boehringer Ingelheim | 8 | $185 |
| AstraZeneca | 9 | $152 |
| Bayer | 7 | $135 |
| Exact Sciences | 6 | $87 |
| Dynavax Technologies Corporation | 4 | $73 |
| Teva Pharmaceuticals USA, Inc. | 5 | $60 |
| Astellas Pharma US Inc | 3 | $47 |
| Supernus Pharmaceuticals, Inc. | 2 | $43 |
| Novartis | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Radius Health, Inc. | 1 | $32 |
| Dexcom, Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Seqirus USA Inc | 1 | $28 |
| Insulet Corporation | 2 | $25 |
| Johnson & Johnson | 2 | $24 |
| Genentech USA, Inc. | 2 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SHINGRIX$339,968
- BEXSERO$138,815
- AREXVY$136,332
- CAPVAXIVE$30,844
- GARDASIL 9$11,888
- PNEUMOVAX 23$11,613
- GARDASIL$9,280
- ABRYSVO$9,093
- PENBRAYA$5,656
- FLUZONE HIGH-DOSE$5,594
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$4,771
- VAXNEUVANCE$3,277
- FLUZONE QUADRIVALENT$2,691
- NURTEC ODT$1,200
- FLUZONE QUADRIVALENT NORTHERN HEMISPHERE$1,065
How this compares
$733,695 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $121,472 |
| JardianceEmpagliflozin | 85 | $115,592 |
| MounjaroTirzepatide | 54 | $81,911 |
| TrulicityDulaglutide | 19 | $29,183 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $24,249 |
| Spiriva RespimatTiotropium Bromide | 26 | $18,493 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $15,798 |
| EliquisApixaban | 14 | $14,808 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $13,084 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,126 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $4,910 |
| Levemir FlexpenInsulin Detemir | 12 | $3,980 |
| Rosuvastatin Calcium | 351 | $3,775 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $2,667 |
| Gabapentin | 117 | $2,487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $185 | $134,085111 claims |
| Novo NordiskOzempic | $343 | $121,47295 claims |
| Lilly USA, LLCMounjaro, Trulicity | $265 | $111,09373 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $152 | $29,15947 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $633,539 | $20,92435 claims |
| PfizerEliquis, Paxlovid | $19,029 | $16,22125 claims |
| MerckJanumet Xr | $67,784 | $13,08416 claims |
| AbbVieSynthroid | $257 | $2,05719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Arlington
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.